Usefulness of serum brain natriuretic peptide level for screening hemodynamically significant patent ductus arteriosus in preterm neonates

Iranian Journal of Pediatrics

Volumn 24, Issue 6, 2014, Pages 769-772

  Khosroshahi, Ahmad Jameii ^a   Kianfar, Ali ^b   Aharanjani, Behzad Mohammadpour ^c,d   Zanjani, Keyhan Sayadpour ^c,e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Brain natriuretic peptide; Echocardiography; Ibuprofen; Patent ductus arteriosus

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; IBUPROFEN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MALE; NEWBORN; PATENT DUCTUS ARTERIOSUS; PREDICTIVE VALUE; PREMATURITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 84922432911     PISSN: 20082142     EISSN: 20082150     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bagnoli F, Rossetti A, Casucci M, et al. Aminoterminal B-type natriuretic peptide (NT-proBNP) in the therapy of patent ductus arteriosus. Minerva Pediatr 2010;62(3 SUPPL 1):67-70.
2. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115(3):e255-61.
3. da Graca RL, Hassinger DC, Flynn PA, et al. Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics 2006; 117(6):2183-9.
4. Eerola A, Jokinen E, Boldt T, et al. The influence of percutaneous closure of patent ductus arteriosus on left ventricular size and function: a prospective study using two-and three-dimensional echocardiography and measurements of serum natriuretic peptides. J Am Coll Cardiol 2006; 47(5):1060-6.
5. Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2003; 88(6):F464-6.
6. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344(26):1966-72.
7. Archer LN, Glass EJ, Godman MJ. The silent ductus arteriosus in idiopathic respiratory distress syndrome. Acta Paediatr Scand 1984;73(5):652-6.
8. Davis P, Turner-Gomes S, Cunningham K, et al. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatr Adolesc Med 1995;149(10): 1136-41.
9. Mellander M, Larsson LE, Ekstrom-Jodal B, et al. Prediction of symptomatic patent ductus arteriosus in preterm infants using Doppler and M-mode echocardiography. Acta Paediatr Scand 1987;76(4): 553-9.
10. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994; 30(5):406-11.
11. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135(5 PART 1):825-32.
12. Kocharian A, Shabanian R, Rahimzadeh M, et al. N-terminal pro-B-type natriuretic peptide and ventricular dysfunction in children and adolescents. Cardiol Young 2009; 19(6):580-8.
13. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001; 90(2):184-91.
14. Puddy VF, Amirmansour C, Williams AF, et al. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002; 103(1):75-7.
15. Flynn PA, da Graca RL, Auld PA, et al. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005; 147(1): 38-42.
16. Sanjeev S, Pettersen M, Lua J, et al. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005; 25(11):709-13.
17. Kunii Y, Kamada M, Ohtsuki S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003; 57(4):191-7.
18. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-9.
19. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31: 202-8.
20. Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol 2001; 6(1):49-61.
21. Maisel AS, Cloton P, Krishnawamy P, et al. Rapid management of B-type natriuretic peptide in the emergency diagnosis od heart faiure. Am Heart J 2004; 147(6).
22. Czernik C, Lemmer J, Metze B, et al. B-type natriuretic peptide to predict ductus intervention in infants <28 weeks. Pediatr Res 2008; 64(3):286-90.
23. Attridge JT, Kaufman DA, Lim DS. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009;94(3):F178-82.
24. Farombi-Oghuvbu I, Matthews T, Mayne PD, et al. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008;93(4):F257-60.